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KDM1Aa b s t r a c t
MicroRNAs (miRNAs) act as key regulators of multiple cancers. miR-329 functions as a tumor sup-
pressor in some malignancies. However, its role in neuroblastoma remains poorly understood.
We found that miR-329 was decreased in metastatic tumor tissues compared with matched primary
tumor tissues. Forced overexpression of miR-329 substantially suppressed cell proliferation, colony
formation, migration, and invasion of neuroblastoma cells. Lysine-speciﬁc demethylase 1 (KDM1A)
was found to be a target of miR-329. Furthermore, down-regulation of KDM1A by shRNA performed
similar effects with overexpression of miR-329. Overexpression of KDM1A partially reversed the
tumor suppressive effects of miR-329 in neuroblastoma cells. Collectively, miR-329 may suppress
neuroblastoma cell growth and motility partially by targeting KDM1A.
 2013 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Neuroblastoma (NB) is one of the most common extracranial
childhood tumors, accounting for 7% of childhood malignancies
and >15% of all childhood cancer deaths [1]. NB originates from
precursor cells of the sympathetic nervous system, and its clinical
hallmark is heterogeneity, ranging from spontaneous regression to
rapid disease progression and mortality [2]. Despite recent thera-
peutic improvements in NB treatment, the overall 5-year survival
rate remains poor. 73% of NB patients have already developed
malignant lesions at the time of diagnosis [3]. Although multiple
genetic and molecular lesions have been found to be associated
with NB tumorigenesis, the molecular mechanism of this tumor
is still poorly understood. Elucidating the molecular mechanism
will contribute to identify of suitable therapeutic agents for NB.
MicroRNAs (miRNAs) are a class of small non-coding RNA mol-
ecules, 19–25 nucleotides in length that regulate gene expression
posttranscriptionally by targeting mRNAs [4]. MiRNAs bind to the
30-untranslated region (30-UTR) of target mRNAs leading to transla-
tional repression or degradation of mRNA. Moreover, single miRNA
can regulate multiple mRNAs and single mRNA can be targeted by
numerous miRNAs as well. MiRNAsmight serve as new therapeutic
strategies for cancers, as they can act as tumor suppressors or as
oncogenes dependent on their target mRNAs [5]. In primaryneuroblastomas, miRNA expression proﬁles have been studied,
and several miRNA clusters have been investigated [6,7]. MiRNAs
are thought to play critical roles in cell proliferation, migration
and invasion in cancer [8,9]. MiR-329 is located on 14q32.31 and
is downregulated in several cancers, including NB [10,11].
In this study, we identiﬁed the important molecular mechanism
by which miR-329 exerted its tumor suppressive effects on neuro-
blastoma cell proliferation, migration and invasion, which involved
the direct targeting the 30-UTR of lysine-speciﬁc demethylase 1
(KDM1A) mRNA.
2. Materials and methods
2.1. Human tissues, cell culture and transfection
34 NB tissues from patients with metastasis and matched pri-
mary tissues were obtained from our department. The diagnoses
of these tissue samples were veriﬁed by pathologists. This work
was approved by the Ethics Committee of Union Hospital. The hu-
man NB cell lines, SH-SY5Y, SHEP, SK-N-BE, and IMR-32, and the
human embryonic kidney cell line HEK-293 were cultivated in
RPMI1640 medium supplemented with 10% FBS, streptomycin
(100 lg/ml), and penicillin (100 U/ml) and maintained in a incuba-
tor at 37 C with 5% CO2. MiR-329 mimics and inhibitors were pur-
chased from RiboBio (Guangzhou, China). Transfections of miRNA
mimics and inhibitors were carried out using Lipofectamine-2000
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
protocol.
Fig. 1. miR-329 was decreased in metastatic NB compared to primary NB. (A) The
expression of miR-329 in metastatic NB compared and primary NB was detected by
qRT-PCR. The relative expression of miR-329 was normalized to U6. ⁄P < 0.05
compared with control group.
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RNA was extracted from tissues or cells using the mirVana miR-
NA Isolation Kit (Ambion, Carlsbad, CA, USA) according to the man-
ufacturer’s instructions. cDNA was obtained using M-MLV
(Promega, Madison, WI, USA). The relative level of miR-329 was
detected by using SYBR Premix Ex TaqTM Kits (TaKaRa, Tokyo,
Japan) on an ABI 7500 thermocycler (Applied Biosystems, Foster
City, CA, USA), and U6 was used as an endogenous control. The
primers were purchased from GeneCopoeia (Carlsbad, CA, USA).
2.3. Plasmids
KDM1A shRNA was obtained from Applied Biosystems (Foster
City, CA, USA). pcDNA3-KDM1Awas generated by using the follow-
ing primers: forward, 50-CGGAATTCGGCGGCCCGAGATGTTAT-30
and reverse, 50-CCCTCGAGTGGGCCTCTTCCCTTAGAAT-30. The PCR
fragment was inserted into pcDNA3.0 within EcoRI and XhoI
restriction sites (Invitrogen, Carlsbad, CA, USA). The 30-UTR of
KDM1A mRNA was ampliﬁed from human cDNA using the follow-
ing primers: forward, 50-CCCTCGAGGCACAGGGAGGAACTT-30 and
reverse, 50-TTGCGGCCGCACAAAAACCCCACACACC-30. The PCR frag-
ment was cloned into psiCHECK2 vector within XhoI and NotI
restriction sites (Promega, Madison, WI, USA). Mutation in the
miR-329 binding sequences of KDM1A was performed by using a
fast mutation kit (Santa Clara, CA, USA).
2.4. Cell proliferation analysis
Cell viability was measured using the MTT assay. The viability
of SH-SY5Y cells transfected with miR-329 or control mimics was
detected every 24 h after transfection. 100 lL MTT (10 mg/mL)
was added to each well of the 96-well plates and incubated for
4 h, then the reaction was terminated by DMSO. The optical den-
sity (OD) at 490 nm was detected using a Microplate Reader
(Bio-Tek Instruments, Winooski, VT, USA).
2.5. Colony formation assay
Transfected SH-SY5Y cells were seeded in 6-well plates with a
density of 200 cells/per well, and cultured in DMEM supplemented
with 10% FBS at 37 C with 5% CO2 for 2 weeks. The cells were
washed twice with ice-cold PBS, and ﬁxed with 4% paraformalde-
hyde (PFA), stained with Gimsa for 15 min. The colony numbers
were counted under a microscope.
2.6. Cell migration and invasion assays
Transfected SH-SY5Y cells were seeded in the upper compart-
ments of the 8-lm Boyden chamber (BD Biosciences, San Jose,
CA, USA). Migration and invasion assays were carried out with
coated Matrigel (invasion) or uncoated Matrigel (migration). After
incubation for 48 h, cells migrated and invaded through the lower
chamber were ﬁxed with methanol, stained with 0.5% Giemsa, and
photographed under the microscope.
2.7. Western blotting
Total protein from cells were lyzed by RIPA buffer. Equal
amount of proteins were separated by 10% SDS–PAGE, and trans-
ferred to PVDF membrane (Millipore, Billerica, MA, USA), and incu-
bated with primary antibodies against KDM1A (Cell Signaling,
Beverly, MA, USA) and GAPDH (Millipore, Billerica, MA, USA), fol-
lowed by HRP labeled secondary antibodies for 1 h at room tem-
perature. Blots were visualized the ECL Detection Reagents
(Amersham Biosciences, Uppsala, Sweden).2.8. Luciferase assay
HEK-293 cells were seeded in a 24-well plate with a density of
2  105 cells/per well, and co-transfected with WT 30-UTR or Mut
30-UTR and miR-329 or control mimics. Cells were collected 48 h
after transfection, and ﬁreﬂy and renilla luciferase luciferase activ-
ities were measured with the Dual-Luciferase Reporter Assay Sys-
tem (Promega, Madison, WI, USA).
2.9. Statistical analysis
Data are expressed as mean ± S.D. Differences were analyzed
using One-way ANOVA or non-paired Student t test by SPSS 16.0.
Differences were considered statistically signiﬁcant at P < 0.05.
3. Results
3.1. miR-329 was decreased in metastatic NB compared to primary NB
Expression of miR-329 in 34 pairs of human tissues was mea-
sured by quantitative Real time PCR (qRT-PCR). MiR-329 was sig-
niﬁcantly decreased in metastatic tumor tissues compared with
matched primary tumor tissues (Fig. 1).
3.2. miR-329 suppressed NB cells viability
To study the effect of miR-329 on NB cell growth, SH-SY5Y cells
were transfected with miR-329 or control mimics. Forced overex-
pression of miR-329 signiﬁcantly suppressed the growth of
SH-SY5Y cells (Fig. 2A). Similarly, overexpression of miR-329
also remarkably suppressed the colony formation of SH-SY5Y
cells (Fig. 2B). The efﬁciency of miR-329 mimics was detected by
qRT-PCR (Fig. 2C).
3.3. miR-329 inhibited NB cells motility
To examine the effect of miR-329 on the motility of NB cells,
miR-329 or control mimics were transfected into SH-SY5Y cells.
In vitro migration and invasion assays were carried out. miR-329
signiﬁcantly repressed the in vitro migration and invasion abilities
of SH-SY5Y cells (Fig. 3A and B).
3.4. KDM1A was a target of miR-329 in NB cells
To screen the function target of miR-329 in NB cells, TargetScan
6.2 was used to screen the target gene of miR-329. KDM1A was
predicted to be a target of miR-329 (Fig. 4A). Luciferase activity as-
say found that miR-329 signiﬁcantly suppressed the luciferase
Fig. 2. miR-329 suppressed NB cells viability. (A) The vitality of SH-SY5Y cells transfected with miR-329 or control mimics was detected using the MTT assay. (B) Colony
formation assay of SH-SY5Y cells transfected with miR-329 or control mimics. (C) The expression of miR-329 in SH-SY5Y cells transfected with miR-329 or control mimics.
Data were drawn from three independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01 compared with control group.
Fig. 3. miR-329 inhibited NB cells motility. Transwell assay was used to evaluate migration and invasion of SH-SY5Y cells transfected with miR-329 or control mimics.
Representative ﬁelds of migration (A) or invasive (B) cells on membrane. Data were drawn from three independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01 compared with control
group.
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SY5Y cells (Fig. 4B). In addition, overexpression of miR-329 signif-
icantly inhibited KDM1A protein level, while inhibition of miR-329
by miR-329 inhibitor remarkably suppressed KDM1A protein level
in SH-SY5Y cells (Fig. 4C).
3.5. Inhibition of KDM1A showed similar effect with miR-329
overexpression
To study the effect of KDM1A on NB cell growth, SH-SY5Y cells
were transfected with KDM1A or the control shRNAs. Inhibition of
KDM1A by shRNA signiﬁcantly suppressed the growth, migration,and invasion of SH-SY5Y cells (Fig. 5A–D). The effect of KDM1A
shRNA was detected by Western blotting (Fig. 5E).
3.6. KDM1A overexpression attenuated the suppressive effect of miR-
329
We further investigated whether overexpression of KDM1A
could reverse the suppressive effect of miR-329. MTT assay
(Fig. 6A), migration and invasion (Fig. 6B and C) shown that over-
expression of KDM1A could signiﬁcantly reverse the suppressive
effect of miR-329 on SH-SY5Y cells. The effect of pcDNA3-KDM1A
was conﬁrmed by Western blotting (Fig. 6D).
Fig. 4. KDM1A was a target of miR-329 in NB cells. (A) A schematic illustration of WT and Mut 30-UTR of KDM1A. (B) Luciferase activity assay shown that miR-329 suppressed
WT KDM1A 30-UTR luciferase activity, while it had no effect on Mut KDM1A 30-UTR luciferase activity compared to control in HEK-293 cells. (C) Expression of KDM1A was
detected byWestern blotting in SH-SY5Y cells transfected with miR-329 or control mimics/inhibitors. GAPDHwas used as a control. Data were drawn from three independent
experiments. ⁄P < 0.05, ⁄⁄P < 0.01 compared with control group.
Fig. 5. Inhibition of KDM1A showed similar effect with miR-329 overexpression. (A) The vitality of SH-SY5Y cells transfected with KDM1A or the control shRNAs was detected
using the MTT assay. (B) Colony formation assay of SH-SY5Y cells transfected with KDM1A or the control shRNAs. Transwell assay was used to detect migration (C) and
invasion (D) of SH-SY5Y cells transfected with KDM1A or the control shRNAs. (E) Protein level of KDM1A was detected by Western blotting in SH-SY5Y cells transfected with
KDM1A or the control shRNAs. Data were drawn from three independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01 compared with control group.
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Fig. 6. KDM1A overexpression attenuated the suppressive effect of miR-329. (A) SH-SY5Y cells were co-transfected with miR-329 and KDM1A or the vector. MTT assay was
used to measure the proliferation. Migration (B) and invasion (C) assays of SH-SY5Y cells co-transfected with miR-329 and KDM1A or the vector. (D) Expression of KDM1A
was detected by Western blotting in SH-SY5Y cells transfected with KDM1A or the vector. Data were drawn from three independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01
compared with control group. #P < 0.05, ##P < 0.01 compared with miR-329 group.
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MicroRNAs play important roles in multiple aspects of tumor
biology. Xiao et al. reported that miR-329 was down-regulated in
glioma, and inhibited cell proliferation of glioma cells by regulating
E2F1-mediated inhibition of Akt pathway [12]. MiR-329 has been
found to be a suppressor of angiogenesis by targeting CD146, an
endothelial biomarker which was aberrantly upregulated during
pathological angiogenesis and acted as a coreceptor of vascular
endothelial growth factor receptor 2 (VEGFR2) to promote disease
progression [10]. Furthermore, miR-329 plays an essential role in
mediating peptidoglycan (PDG)-induced trophoblast apoptosis
and suppression of IL-6 expression by targeting the NF-jB subunit,
p65 [13]. Here, we report that miR-329 was down-regulated in
metastatic NB compared to primary NB, suggesting a potential tu-
mor-suppressive function of miR-329. We demonstrate that miR-
329 decreased cell viability, proliferation, migration, and invasion
of NB cells in vitro, and provide evidence that these effects were
partially mediated by inhibiting KDM1A expression. We show that
KDM1A knockdown performed similar effects of miR-329 overex-
pression on NB cells, and moreover, overexpression of KDM1A sub-
stantially reversed the tumor-suppressive effects of miR-329.
These results support KDM1A as a direct target gene of miR-329,
important in regulating NB tumor biology.
KDM1A has been reported to contribute to the tumorigenesis of
multiple cancers [14–16]. Huang et al. reported that KDM1A was
higly expressed in colorectal carcinoma, and KDM1A knockout
colorectal cancer cells were less tumorigenic. They demonstrated
that KDM1A contributed to colorectal tumorigenesis via activating
the Wnt/b-catenin signaling pathway [17]. Yu et al. found that
High expression of KDM1A correlated with poor prognosis of
esophageal squamous cell carcinoma, and it might serve as a po-
tential prognostic maker [18]. Moreover, Kashyap et al. found that
in prostate cancer the expression of KDM1A was correlation withthe expression of VEGF-A and cyclin A1, key factors which regu-
lated angiogenesis and tumor invasion [19]. Positive expression
of KDM1A and negative expression of E-cadherin had been found
to correlate with poor prognosis of colon cancer [20]. In addition,
Jin et al. reported that loss of KDM1A suppressed the growth of co-
lon cancer cells [21]. In the present study, we found that inhibition
of KDM1A remarkably suppressed the growth and motility of NB
cells. Our study expaned the function of KDM1A in NB.
Collectively, our data establish a functional link between miR-
329 and KDM1A expression in NB, demonstrating that KDM1A
was directly target of miR-329, which was expressed at lower lev-
els in aggressive NB. Restoring miR-329 function might provide an
alternative approach to attenuate aggressive tumor properties by
reducing therapeutically KDM1A expression.
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